Q-omics provides the consensus-scored TRMT6 profile across patient tissues and cancer cell-line models. TRMT6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TRMT6 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, TRMT6 protein abundance shows 26,402 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, HNSC, and LSCC as cancer lineages where TRMT6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRMT6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRMT6 survival associations across molecular data types. TRMT6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRMT6 RNA expression–survival associations across cancer types. High TRMT6 expression shows unfavorable associations in LIHC, KIRP, ACC, LGG, MESO and PAAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TRMT6 RNA expression.
This table summarizes TRMT6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TRMT6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRMT6 shows higher tumor expression in HNSC, COAD, BLCA, STAD, LIHC and LUAD. The HNSC box plot shows higher TRMT6 RNA expression in tumor versus normal tissue (log2 FC = +1.359, t-test p < 0.001).
This table shows molecular features associated with TRMT6 in patient tissues and cancer cell lines. In patient samples, TRMT6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRMT6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
